Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700449 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
A Phase 2 study, sponsored by Connect Biopharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
NCT04700449: Completed Phase 2 study, sponsored by Connect Biopharm.
NCT04700449 is a Phase 2 study that has completed, run by Connect Biopharm. The registered enrollment target is 145 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04700449, a Phase 2 study, has completed, sponsored by Connect Biopharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
Primary Outcome
Change in adapted Mayo score from baseline at week 12 compared between CBP-307 0.2 mg and placebo in the Full Analysis Set by Multiple Imputation. Adapted Mayo scores were calculated based on data in stool frequency, rectal bleeding, and endoscopic findings. The Mayo scores range from 0 to 9 and consist of 3 subscores, each ranging from 0 to 3. The higher the score is, the more severe the disease is.
Interventions
- DRUG Double-Blind 0.2mg CBP-307
- DRUG Double-Blind Placebo
- DRUG Open-label CBP-307
- DRUG Double-Blind 0.1mg CBP-307
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2022-11-10 |
| Phase | Phase 2 |
What the finished NCT04700449 record still lists
NCT04700449 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Double-Blind 0.2mg CBP-307 is the first listed.
NCT04700449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04700449 about?
NCT04700449 is a clinical study titled "A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)". This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
What is the current status of trial NCT04700449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2019-02-27. Estimated completion is 2022-11-10.
What interventions are being tested in trial NCT04700449?
The interventions under investigation include: Double-Blind 0.2mg CBP-307 (DRUG), Double-Blind Placebo (DRUG), Open-label CBP-307 (DRUG), Double-Blind 0.1mg CBP-307 (DRUG).
Who is sponsoring clinical trial NCT04700449?
This trial is sponsored by Connect Biopharm, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04700449's enrollment target sits among peer trials
145 498th of 2000 higher than 1,501 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI